Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed is poised for long-term success as their two commercial products show strong potential and their robust clinical pipeline targets key therapeutic areas with significant unmet needs. The company's recent impressive financial results and guidance from the Brinsupri launch, combined with their promising peak revenue estimates for both Brinsupri and TPIP, position them for continued growth and potential upside. However, risks such as potential competition, clinical and regulatory obstacles, and commercialization challenges should be monitored closely.

Bears say

Insmed is a biopharmaceutical company with a diverse portfolio of respiratory and inflammatory assets. Despite its strong commercial and clinical programs, the company has a history of significant financial losses and a high level of debt. Additionally, its commercial products Arikayce and Brinsupri have limited peak sales potential, and its pipeline program for TPIP faces potential challenges with a small sample size and lack of measured primary endpoints.

Insmed (INSM) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 20 analysts, Insmed (INSM) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $208.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $208.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.